Comparing VistaGen Therapeutics (NASDAQ:VTGN) & Alto Neuroscience (NYSE:ANRO)

VistaGen Therapeutics (NASDAQ:VTGN) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Institutional and Insider Ownership

78.4% of VistaGen Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares VistaGen Therapeutics and Alto Neuroscience”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$490,000.00	50.60	-$51.42 million	($1.89)	-0.33
Alto Neuroscience	N/A	N/A	-$63.24 million	($2.18)	-11.42

VistaGen Therapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for VistaGen Therapeutics and Alto Neuroscience, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1	4	0	0	1.80
Alto Neuroscience	1	1	6	0	2.63

VistaGen Therapeutics currently has a consensus target price of $0.95, indicating a potential upside of 51.81%. Alto Neuroscience has a consensus target price of $35.14, indicating a potential upside of 41.16%. Given VistaGen Therapeutics’ higher possible upside, research analysts clearly believe VistaGen Therapeutics is more favorable than Alto Neuroscience.

Risk & Volatility

VistaGen Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.

Profitability

This table compares VistaGen Therapeutics and Alto Neuroscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
Alto Neuroscience	N/A	-47.64%	-37.83%

About VistaGen Therapeutics

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

About Alto Neuroscience

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.